How does regenerative prolotherapy work?
Prolotherapy uses small injections of a dextrose (sugar-water) solution into damaged ligaments, tendons, or joint structures to prompt the body's own repair response. It works differently from a corticosteroid injection, which calms inflammation, and from PRP, which uses platelets concentrated from the patient's own blood.
The "prolo" name comes from "proliferative." The original 1950s theory was a controlled irritation that drove tissue repair. Current research has moved the story on, showing that in clinical doses, dextrose appears to work mainly through tissue-building (anabolic) signaling on connective tissue and, for nerve-targeted versions, has anti-inflammatory effects on small peripheral nerves. There are three different types of prolotherapy: dextrose prolotherapy, perineural injection therapy (PIT), and ultrasound-guided hydrodissection.
What conditions is it used for?
Knee osteoarthritis
Chronic low back and sacroiliac joint pain
Lateral epicondylitis (tennis elbow) and other tendinopathies
Plantar fasciitis and Achilles tendinopathy
Carpal tunnel syndrome and other peripheral nerve entrapments (PIT)
Chronic musculoskeletal pain that has not responded to physical therapy and medication
Prolotherapy works best when it is matched to an indication the evidence supports, and used as part of a plan that includes rehab and load management.
What to expect during treatment
Patients get pain reduction and improved function for the indications with evidence behind them, most notably knee osteoarthritis and several tendinopathies (long-standing tendon pain conditions). The visit itself runs 30 to 60 minutes, including local anesthetic to numb the area and, for deeper targets, ultrasound guidance. The dose and concentration the clinician administers depend on the area being treated.
The course runs a set number of sessions, then you stop. Classical dextrose protocols use 3 to 6 sessions spaced 2 to 4 weeks apart; PIT is usually weekly. Most patients can tell after 2 or 3 sessions whether they are responding. When benefit lands, it typically holds months to a year or two, and re-treatment is only needed if symptoms come back. Long-term data beyond that is limited.
What prolotherapy is
Prolotherapy is a regenerative injection therapy that uses a dextrose solution to stimulate tissue and nerve healing. The body's own repair response does the work; the dextrose triggers that response rather than acting as a drug.
Three distinct forms sit under the same umbrella, and they are not interchangeable:
Dextrose prolotherapy. 12.5–25% dextrose injected into ligaments, tendons, joint entheses (where tendons and ligaments attach to bone), or joint capsules. This is the original protocol developed by George Hackett and Gustav Hemwall in the mid-20th century, carried forward by the modern research-era work that now anchors the clinical literature.
Perineural injection therapy (PIT, also called neural prolotherapy; the article uses "PIT" from here on). 5% dextrose injected just under the skin, adjacent to small peripheral nerves. Originated by John Lyftogt, the New Zealand physician who developed the method in the 2000s.
Ultrasound-guided hydrodissection. 5–10% dextrose injected using continuous ultrasound guidance to free deeper peripheral nerves from surrounding fascia.
The three forms of prolotherapy are sometimes lumped together, but they differ in concentration, anatomic target, evidence base, and protocol, and this article treats them separately throughout.
How prolotherapy works (in depth)
The original framing was that when injected, dextrose acts as a controlled irritant that triggers an anti-inflammatory response, activating the body's healing cascade, resulting in tissue repair. Current research has revised that view, as K. Dean Reeves (the physiatrist, a rehabilitation medicine physician, who has authored or co-authored more of the prolotherapy clinical literature than anyone else) has summarized in recent talks. In animal work, dextrose injections produced no more inflammation than saline or a needle stick alone (Han et al., 2021).
For connective tissue, the leading model is anabolic (tissue-building) signaling rather than energy metabolism. In a chronic-muscle-pain mouse model, dextrose-mediated analgesia depended on activation of a cell receptor (ASIC1a) and release of substance P from muscle afferents (Han et al., 2021); tissue-building (anabolic) signaling is supported separately by in-vitro fibroblast work with dextrose concentrations of 5% or higher and volumes above 10 microliters required for the effect; osmolarity (the fluid's solute concentration) alone was not sufficient (Han et al., 2021). In-vitro fibroblast work (cell-culture studies of the cells that build connective tissue) converges on a similar picture (Harting et al., 2026).
For nerve-targeted PIT, Lyftogt has proposed a C-fiber glycopenia model: that small unmyelinated fibers carrying chronic pain signals misfire when locally glucose-deprived, and low-dose dextrose dampens neurogenic inflammation. The mechanism remains hypothesis-level; direct human evidence is limited to case series and small trials.
The mechanism update also helps explain the course shape: Once the series of injections triggers the body's repair process, the body takes over, which is why patients don't need lifetime treatments.
How prolotherapy is used in practice
Prolotherapy is matched to specific indications, not used universally. We've listed the uses below in order of the strength of evidence behind each. For each, the protocol and the answer to "how long is prolotherapy treatment" are spelled out so you can compare each against your own situation.
Knee osteoarthritis
This is the most-studied indication. A 90-person randomized trial showed dextrose prolotherapy produced significantly greater pain-and-function improvement (measured on a standard arthritis score) than saline or home exercise, sustained to 52 weeks (Rabago et al., 2013); a meta-analysis of 14 trials in 978 patients confirmed the pattern (Chen et al., 2022). Protocol matters. Combined intra-articular plus extra-articular injection (both inside the joint capsule and into the ligaments and tendons around it) performs better than intra-articular alone. A typical treatment course is 3 to 6 sessions over 2 to 3 months. Many patients use it to defer or avoid knee replacement.
Lateral epicondylitis and other tendinopathies
A systematic review found consistent pain and function improvement for tennis elbow (Arias-Vázquez et al., 2022), with the VA review finding the same benefits at short-term and medium-term follow-up (Ewart et al., 2024). A typical treatment course is 3 to 4 sessions; mid-term outcomes are roughly comparable to PRP for some tendinopathies. See our guide to PRP therapy for the side-by-side.
Plantar fasciitis and Achilles tendinopathy
This indication showed the clearest benefit when compared to saline in the VA review (Ewart et al., 2024). A typical treatment course is 3 to 4 sessions. Outcomes are similar to extracorporeal shockwave therapy rather than better, so prolotherapy is a common pick when shockwave or PRP is not accessible. See our guide to shockwave therapy.
Chronic low back and sacroiliac joint pain
A 110-person trial found prolotherapy with a glucose-lignocaine solution into lumbopelvic ligaments (the ligaments connecting the lower spine to the pelvis) produced meaningful pain and disability reductions, though saline injections also produced the same improvements (Yelland et al., 2004). Cochrane and VA reviewers have been more cautious here, partly because the full Hackett-Hemwall protocol (the gold-standard method for prolotherapy treatment) is rarely used in trials.
Carpal tunnel and entrapment neuropathies (conditions where nerves get compressed or irritated by surrounding tissue) treated with PIT
This is where the strongest comparative-effectiveness evidence in the whole prolotherapy literature sits. Perineural 5% dextrose improved symptom severity, function, electrophysiological measures, and median-nerve cross-sectional area at 6 months versus saline (Wu et al., 2017), and a head-to-head trial against a corticosteroid found dextrose more effective at 6 months (Wu, 2018). PIT is given weekly. See our deeper look at prolotherapy for chronic pain for adjacent uses.
What the evidence supports
Evidence quality varies by indication. The strongest signals come from a small set of well-designed trials and meta-analyses:
Knee osteoarthritis: Rabago et al. (2013) for 52-week durability in a 90-person trial, and Chen et al. (2022) pooling 14 trials in 978 patients. A foundational placebo-controlled trial showed improvement in pain, swelling, knee buckling, and flexion at 6 and 12 months (Reeves & Hassanein, 2000).
Lateral epicondylitis: a positive systematic review (Arias-Vázquez et al., 2022) plus a positive signal in the VA review (Ewart et al., 2024).
Plantar fasciitis: short- and medium-term benefit vs saline (Ewart et al., 2024).
Carpal tunnel syndrome with PIT: two randomized trials, including a head-to-head against a corticosteroid (Wu et al., 2017; Wu, 2018).
Chronic low back pain: a 110-person trial with meaningful pain and disability reduction, with the caveat that the saline arm also improved (Yelland et al., 2004).
Most individual trials are small to moderate in size, and protocols vary widely across the literature.
Where the evidence is limited
The U.S. Veterans Affairs Evidence Synthesis Program, in its 2024 systematic review of 90 prolotherapy studies, rated most of the evidence as "low" or "very low" certainty under GRADE methodology (the standard system reviewers use to grade confidence in a finding), even where the direction of effect was positive (Ewart et al., 2024). For intra-articular knee OA injection alone, the review found probably little to no benefit vs saline. For shoulder pain, prolotherapy probably performs worse than a corticosteroid.
Reeves and others in the academic-prolotherapy community push back on parts of that picture, arguing that many failed trials use inadequate session counts or single injections instead of the full Hackett-Hemwall protocol, neither of which match the protocols used in clinical practice. Both readings can hold: the published trial set is heterogeneous, and high-confidence comparative-effectiveness data is not there yet.
Long-term durability beyond 1–2 years is thin across most indications, and head-to-head trials against PRP, shockwave, and surgery are largely missing.
Safety and regulation
The safety record is one of the cleaner ones in regenerative medicine. A survey-based analysis reported mostly mild, short-lived adverse events, with serious events being rare and mainly occurring in non-ultrasound-guided spinal injections performed by inexperienced providers (Dagenais et al., 2006). The AAPM&R reference describes the side-effect profile as more favorable than corticosteroid injections. The most common side effect is post-injection soreness for 1 to 3 days along with transient stiffness.
Prolotherapy is not recommended for people who have an active local infection, bleeding disorders, or an allergy to anesthetic or any of its components, such as lidocaine, and those who are pregnant. Uncontrolled diabetes is a relative consideration rather than an absolute contraindication, since dextrose concentration likely matters, though this has not been formally trialed.
Dextrose injection is not an FDA-approved indication, so physicians use it off-label. There is no Current Procedural Terminology (CPT) code for it, which is why insurance does not cover it. Out-of-pocket cost in the U.S. typically runs $200 to $500 per session.
The experience
Booking usually starts with a clinical assessment, often including ultrasound, to identify which structures are likely generating the pain and whether the indication has evidence behind it. An experienced injector will say when prolotherapy is a good match and when it is not.
In the room, the clinician numbs the area with lidocaine, then delivers the dextrose solution in multiple small injections around the affected structure, with ultrasound guidance for deeper targets like joint capsules and peripheral nerves. The injection itself takes a few minutes; the full visit runs 30 to 60 minutes.
You can expect to feel a sharp pinch and pressure, but most patients tolerate it well. PIT, with its superficial 5% dextrose and very short needle, is significantly less uncomfortable than traditional deeper injections.
Aftercare is easy. Post-injection soreness lasts 1 to 3 days. You can apply ice or heat to help with soreness and take acetaminophen. NSAIDs, like ibuprofen, should be avoided for 48 to 72 hours because they can suppress your body's inflammatory healing response and potentially reduce the effectiveness of the treatment. Light activity is fine, but heavy load on the treated area should be avoided.
The treatment course is short with 3 to 6 sessions over 2 to 3 months for dextrose or weekly for PIT. Most patients know after 2 or 3 sessions whether they are responding to treatment.
The future of prolotherapy
As preclinical work continues to map dextrose's anabolic and anti-inflammatory pathways, researchers will continue to gain a better understanding of how prolotherapy works (Arias-Vázquez et al., 2026). The most useful next step for clinician decision-making is direct head-to-head trials of prolotherapy against PRP, shockwave, and corticosteroid for the same indications. How effective these treatments are in comparison to each other remains an important unanswered question. Larger and better-protocolled replications of the strongest findings are also needed, especially for the combined knee OA protocol and PIT in other entrapment neuropathies.
Takeaway
Prolotherapy is an evidence-grounded regenerative injection therapy for a specific set of indications: knee osteoarthritis with the combined protocol, lateral epicondylitis, plantar fasciitis, and carpal tunnel syndrome treated with perineural injection therapy. For these uses, the evidence supports a meaningful benefit for many patients. The typical treatment course is short with a good safety profile. Claims that prolotherapy treats any type of chronic pain haven't yet been confirmed. The most benefit comes from matching prolotherapy to an indication with evidence behind it, working with an experienced ultrasound-guided practitioner, and pairing the treatment with rehab and load management. For wider context, see our broader chronic-pain guide and our guide to PRP therapy.
